Bristol-Myers Squibb (BMY) won approval for its oral hepatitis C virus (HCV) drug Daklinza in the European Union Wednesday, as the company continued to carve out a niche in the increasingly competitive HCV space. The EU approved Daklinza with sofosbuvir, also known as Gilead Sciences ‘ (GILD) Sovaldi, for all genotypes of the disease. This combo performed outstandingly in clinical trials, achieving a 100% cure rate in some groups. But Gilead
Bristol-Myers Squibb won approval in Japan for its all-oral hepatitis C virus (HCV) regimen, an expected but important development for the company as it carves out its place in the crowded HCV market. The stock was down a fraction in midday trading on the stock market today . Bristol-Myers Squibb’s (BMY) therapy is a combination of daclatasvir and asunaprevir , now known by the brand names Daklinza and Sunvepra, respectively. The approval was for
Big pharma Merck reported stellar results for its phase-two hepatitis C (HCV) drug trials Thursday, sparking debate among analysts over its potential to take market share from leader Gilead Sciences. At the International Liver Congress in London, Merck (MRK) reported a 98% cure rate in patients with hepatitis C genotype 1 who took a combination of its drug candidates MK-5172 and MK-8742. With the two potentially combined in one pill